Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

t non-small cell lung cancer, or NSCLC. The trial design was an open label, non-placebo trial with one year follow-up for survival. Sixty-four patients were enrolled in the trial with the last patient enrolled in March 2006.

About UVIDEM(R)

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma GMP manufacturing facilities in Irvine, California and in Paris, France. UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase II clinical trials was previously announced. Thirty-eight patients with malignant melanoma were included in the US Phase II study and 53 patients with resected stage II/III melanoma were included in the European randomized Phase II study.

About EP-2101

The EP-2101 cancer vaccine candidate used in this trial includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004.

About Melanoma

According to the American Cancer Society, in 2007 approximately 59,940 new cases are expected to be diagnosed and it is estimated that approximately 8,110 people in the United Sates will die from the disease.

About Lung Cancer

Cancer of the lungs continues to be a major health problem with a very high mortality rate and represents the leading cause of canc
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/2/2008)... - Dr. Robert Weiss, Director of Maryland Lase... to his practice -, BALTIMORE, Oct. 2 /PRNewswire...gist, is among the first physicians in the U.S. to...ermolysis), the latest,state-of-the-art procedure...ationally renowned dermatologist, who is in privat...
(Date:10/2/2008)... GOTEBORG, Sweden, October 2 /- C...ated dose study in xerostomia ("dry mouth"),patien... be studied in 45,dry mouth patients between the a...select a dose for evaluation in a succeeding Phase...ning the cholinesterase inhibitor,physostigmine. I...
(Date:10/2/2008)... QUEBEC CITY, Oct. 2 / ...a global biopharmaceutical company focused on,endo... has entered the,second stage of patient recruitme...ZS-108, a luteinizing hormone-releasing hormone (L...o enter the second stage of patient,recruitment wa...
(Date:10/2/2008)... OXFORD, England, October 2 /- Ci... focused on the fields of allergy and critical,car... clinical study of its,ToleroMune(R) technology in...itive results achieved in an earlier phase II stud...its of the ToleroMune approach to allergy,desensit...
Breaking Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Research uncovers the social dynamics of yellow jackets 2253 1Research uncovers the social dynamics of yellow jackets 2253 2Research uncovers the social dynamics of yellow jackets 2253 3Research uncovers the social dynamics of yellow jackets 2253 4Why recovery from flu may increase odds of bacterial infection 12136 1Old London Launches Skinny Jeans Contest 12131 1Old London Launches Skinny Jeans Contest 12131 2Old London Launches Skinny Jeans Contest 12131 3Old London Launches Skinny Jeans Contest 12131 4Into the abyss 3A Deep sixing carbon 2249 1Into the abyss 3A Deep sixing carbon 2249 2
...NJ – June 4, 2007 – Genta,Incorporated...lts,from a Phase 2 clinical trial of its marketed ...plus rituximab (Rituxan®;,Genentech/IDEC) and ...ory non-Hodgkin’s lymphoma (NHL). The data w...n Society of Clinical,Oncology (ASCO) in Chicago, ...
... WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.,...ators today,reported updated Phase 2 data demonstr...53, tumor responses and increased,survival followi...quamous cell carcinoma of the head and neck. The d...nnual meeting of the American,Society of Clinical ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4
(Date:10/6/2008)...d civil litigation and criminal defense firm resol...warded $3.2 million to plaintiff earlier this year...((Lexis Nexis) October 6, 2008 -- Attorneys in the...tha & Psoras] have successfully resolved a maj...lder who was awarded more than $3 million by a Bal...
(Date:10/5/2008)...g samples distributed to children may be unsafe, a...ealth Alliance and Hasbro Children,s Hospital. The...mple use among children, appears in the October 20...so serve as researchers at Harvard Medical School ...ersity, found that children commonly receive free ...
(Date:10/5/2008)...l a spider as it scurries across the floor. Those...a plane. While nothing physically stops people wi... from the task at hand. , The same could be said...y, according to research presented at the Obesity ...s from the Center for Obesity Research and Educati...
(Date:10/3/2008)...ing is beneficial. But can it help kids lose weigh...erature on obese adolescents, researchers at Duke ...ght type of novel may make a difference. , The D...ho were already in a comprehensive weight loss pro...Rescue (Beacon Street Press). It was carefully cra...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:Free drug samples carry risks for children 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Duke researchers show reading can help obese kids lose weight 2
...ng cardiologist Naresh Trehan has been reinstated ... following an out-of-court settlement ending their... Fortis Healthcare, which has acquired 90 percent ... and Research Centre (EHIRC), Saturday withdrew th...
...ost significant single predictor of aggressive pro...ostate specific antigen (PSA) levels, according to...t rate of PSA increase, called PSA velocity, of mo... a high risk of death from prostate cancer. Elevat...
...contact lens users beware of the AMO Complete Mois...overnment investigation in the US has found that i... keratitis, a rare yet severe eye infection. The...loss or blindness. The Centres for Disease Control...
...alian Medical Students Association (AMSA) National...private training courses threaten to undermine the...entry into medical school. Media reports today ... are paying as much as $1,700 to attend private tr...
Other Medicine News:Health News:Naresh Trehan Reinstated as Chief of Escorts After Weeklong Row 2Health News:High Pretreatment PSA Velocity Predicts Worse Outcome 2Health News:Contact Lens Wearers Warned Against Using AMO Solution 2Health News:Contact Lens Wearers Warned Against Using AMO Solution 3
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: